Home » Stocks » SRPT

Sarepta Therapeutics, Inc. (SRPT)

Stock Price: $79.15 USD -0.21 (-0.26%)
Updated Jun 21, 2021 12:17 PM EDT - Market open
Market Cap 6.33B
Revenue (ttm) 573.36M
Net Income (ttm) -703.89M
Shares Out 79.45M
EPS (ttm) -8.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $79.15
Previous Close $79.35
Change ($) -0.21
Change (%) -0.26%
Day's Open 79.53
Day's Range 77.38 - 79.56
Day's Volume 565,181
52-Week Range 67.68 - 181.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

Other stocks mentioned: CPB, EXAS, EXEL, SAVE, ZTO
6 days ago - 24/7 Wall Street

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will part...

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 28, 2021 that were p...

3 weeks ago - GlobeNewsWire

Institutional investors and hedge funds wanted nothing to do with these widely owned stocks in the first quarter.

Other stocks mentioned: GME, TSLA
3 weeks ago - The Motley Fool

Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.

1 month ago - Zacks Investment Research

Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price inc...

1 month ago - Zacks Investment Research

Shares of Sarepta Therapeutics (SRPT) closed higher after announcing positive data for its Duchenne Muscular Dystrophy (DMD) drug.

1 month ago - Zacks Investment Research

Sarepta Therapeutics Inc (NASDAQ: SRPT) has announced positive 12-week results from the first 11 participants enrolled in open-label study 9001-103 ENDEAVOR being conducted in partnership with Roche Hol...

1 month ago - Benzinga

CAMBRIDGE, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive 12-week expression and s...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Tuesday, May 18, 2021 at ...

1 month ago - GlobeNewsWire

Analysts believe these fast-growing, innovative businesses are excellent bounce-back candidates over the next 12 months.

Other stocks mentioned: PLUG, ROOT, SKLZ, ZM
1 month ago - The Motley Fool

Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline.

1 month ago - Zacks Investment Research

The company's revenue soared in Q1, but its bottom line still looked ugly.

1 month ago - The Motley Fool

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -4.48% and 4.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first qu...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will parti...

1 month ago - GlobeNewsWire

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced positive results from Part A in a tiny group of 4 patients of the MOMENTUM Phase 2 study evaluating SRP-5051 in Duchenne muscular dystrophy (DMD) patien...

1 month ago - Benzinga

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of t...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Apr. 30, 2021 that wer...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, May 3, 2021 at ...

1 month ago - GlobeNewsWire

Analysts believe these underperformers could nearly double over the next 12 months.

Other stocks mentioned: ICPT, INO
1 month ago - The Motley Fool

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial result...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Sarepta) (Nasdaq:SRPT) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Inv...

1 month ago - GlobeNewsWire

We believe that the stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is u...

1 month ago - Forbes

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important upda...

Other stocks mentioned: AZN, BIIB, JNJ, MRNA, PFE, VRTX
2 months ago - GuruFocus

SRPT stock has some positives going for it but its underlying gene therapy solutions have questions that investors can't shake. The post Positive Spin Isn't Working for Sarepta Therapeutics appeared fir...

2 months ago - InvestorPlace

A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.

2 months ago - The Motley Fool

While revenue continues to grow, the biotech's future hinges on its gene therapy SRP-9001.

2 months ago - The Motley Fool

We believe that ​Sarepta Therapeutics stock, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying...

2 months ago - Forbes

-- Application website is now open for the 2021 Scholarship Program -- -- The Company will award up to 15 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

2 months ago - GlobeNewsWire

An experimental gene therapy from Sarepta Therapeutics showed "remarkable" stability at two years in muscular dystrophy patients, an analyst said Friday as SRPT stock edged higher. The post Can Sarepta'...

3 months ago - Investors Business Daily

-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as measured ...

3 months ago - GlobeNewsWire

With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.

Other stocks mentioned: AVRO, BLUE, BOLD, ORTX, QURE, RCKT
3 months ago - GuruFocus

-- Ten abstracts, including four podium presentations, reflect Sarepta's ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these d...

3 months ago - GlobeNewsWire

Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years, although their stock prices have lagged, due to Covid-19 related disrupti...

Other stocks mentioned: CNC, NBIX
3 months ago - Forbes

Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels[Updated 3/2/2021] Sarepta Update Last month we talked about how Sarepta Therapeutics stock (NASDAQ: SRPT) seems to be a good buying o...

3 months ago - Forbes

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

3 months ago - Zacks Investment Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -20.00% and 1.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 17.20% over the past year to ($1.84),...

3 months ago - Benzinga

– Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference –

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that were...

3 months ago - GlobeNewsWire

Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.

3 months ago - Benzinga

-- AMONDYS 45 is Sarepta's third RNA exon-skipping treatment for DMD approved in the U.S. ---- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately ---- Information for patients a...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will part...

3 months ago - GlobeNewsWire

Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related dis...

Other stocks mentioned: NBIX, VERX
3 months ago - Forbes

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 fi...

3 months ago - GlobeNewsWire

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.

4 months ago - Zacks Investment Research

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.... [Read more...]

Industry
Biotechnology
IPO Date
Jun 3, 1997
CEO
Douglas Ingram
Employees
866
Stock Exchange
NASDAQ
Ticker Symbol
SRPT
Full Company Profile

Financial Performance

In 2020, SRPT's revenue was $540.10 million, an increase of 41.82% compared to the previous year's $380.83 million. Losses were -$554.13 million, -22.51% less than in 2019.

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is 129.00, which is an increase of 62.99% from the latest price.

Price Target
$129.00
(62.99% upside)
Analyst Consensus: Buy